GSA Capital Partners’s Lyell Immunopharma LYEL Stock Holding History

GSA Capital Partners’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Buy	+26,225	New	+$475K	0.02%	1191
2024 Q4	–	Sell	-17,741	Closed	-$490K	–	1848
2024 Q3	$490K	Buy	17,741 +16,460	+1,285%	+$484K	0.04%	920
2024 Q2	$37K	Sell	1,281 -428	-25%	-$20.4K	﹤0.01%	1570
2024 Q1	$76K	Buy	+1,709	New	+$73.2K	0.01%	1510
2023 Q4	–	Sell	-1,727	Closed	-$51K	–	1742
2023 Q3	$51K	Buy	+1,727	New	+$82K	﹤0.01%	1416
2023 Q1	–	Sell	-804	Closed	-$56K	–	1745
2022 Q4	$56K	Buy	+804	New	+$79.9K	0.01%	1352
2022 Q2	–	Sell	-2,350	Closed	-$237K	–	1632
2022 Q1	$237K	Buy	+2,350	New	+$285K	0.03%	1062
2021 Q3	–	Sell	-1,525	Closed	-$495K	–	1631
2021 Q2	$495K	Buy	+1,525	New	+$500K	0.06%	633

Other funds holding LYEL

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

GSA Capital Partners's LYEL Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 26,225 shares worth $368K. The stake represents 0.02% of the portfolio and ranks #1191 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in LYEL as recently as Q3 2024.

GSA Capital Partners first reported a position in LYEL in Q2 2021 and has held it in 8 quarters since. The position peaked at $495K in Q2 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

GSA Capital Partners held 26,225 shares of Lyell Immunopharma worth $368K as of Q2 2026.
Lyell Immunopharma was a new GSA Capital Partners position in Q2 2026.
Lyell Immunopharma made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1191 holding.
GSA Capital Partners first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 8 quarters since.
GSA Capital Partners's Lyell Immunopharma position peaked at $495K in Q2 2021.
87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.